Humanwell Healthcare's HWH217 tablets get clinical trial approval

Humanwell Healthcare Group Co., Ltd. announced today that its wholly-owned subsidiary, Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HWH217 tablets. The drug is classified as a Class 2.3 chemical medicine and is intended for the treatment of Group 1 Pulmonary Arterial Hypertension (WHO Group 1).

The approval allows the company to commence clinical research for HWH217 tablets, which are a new compound formulation containing known active ingredients. According to Insight database statistics, there are currently no other compound formulations approved in China for this indication.

The cumulative research and development investment for this project has reached approximately CNY 6 million. Following the completion of clinical studies, the company plans to submit clinical trial data and other relevant materials to the National Medical Products Administration for production and market approval.